for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ACADIA Pharmaceuticals Inc.

ACAD.OQ

Latest Trade

21.18USD

Change

-0.31(-1.44%)

Volume

1,801,234

Today's Range

20.94

 - 

22.04

52 Week Range

15.68

 - 

54.56

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
21.49
Open
21.41
Volume
1,801,234
3M AVG Volume
33.89
Today's High
22.04
Today's Low
20.94
52 Week High
54.56
52 Week Low
15.68
Shares Out (MIL)
160.76
Market Cap (MIL)
3,454.65
Forward P/E
-21.01
Dividend (Yield %)
--

Next Event

Q4 2021 ACADIA Pharmaceuticals Inc Earnings Release

Latest Developments

More

ACADIA Pharmaceuticals Announces Positive Top-Line Results From Pivotal Phase 3 Lavender Trial Of Trofinetide In Rett Syndrome

Acadia Pharmaceuticals Reports Q3 Sales Of $131.6 Mln

Acadia Pharmaceuticals Inc Says Mark Schneyer Has Been Appointed Acadia's Interim Chief Financial Officer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders. The Company's product pipeline includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist/antagonist, preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome. ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).

Industry

Biotechnology & Drugs

Contact Info

3611 Valley Centre Dr Ste 300

SAN DIEGO, CA

92130-3331

United States

+1.858.5582871

http://www.acadia-pharm.com/

Executive Leadership

Stephen R. Biggar

Independent Chairman of the Board

Srdjan R. Stankovic

President

Stephen R. Davis

Chief Executive Officer, Principal Financial Officer, Director

Mark C. Schneyer

Chief Financial Officer, Executive Vice President

Brendan Teehan

Chief Operating Officer, Executive Vice President and Head of Commercial

Key Stats

2.57 mean rating - 21 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.2K

2019

0.3K

2020

0.4K

2021(E)

0.5K
EPS (USD)

2018

-1.940

2019

-1.600

2020

-1.790

2021(E)

-1.022
Price To Earnings (TTM)
--
Price To Sales (TTM)
7.28
Price To Book (MRQ)
6.09
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-28.73
Return on Equity (TTM)
-25.31

Latest News

Latest News

U.S. FDA accepts Acadia's application for dementia drug

The U.S. Food and Drug Administration on Monday accepted Acadia Pharmaceuticals Inc's application for an antipsychotic drug to treat dementia patients with hallucinations and delusions.

BRIEF-Acadia Submits Supplemental NDA To U.S. FDA For Nuplazid For Treatment Of Delusions Associated With Dementia-Related Psychosis

* ACADIA PHARMACEUTICALS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO U.S. FDA FOR NUPLAZID® (PIMAVANSERIN) FOR THE TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH DEMENTIA-RELATED PSYCHOSIS

Acadia Pharmaceuticals can't duck investor lawsuit over drug's death rate

A federal judge has cleared the way for Acadia Pharmaceuticals Inc to face a proposed shareholder class action alleging it failed to disclose its Parkinson's disease psychosis drug Nuplazid's high death rate.

BRIEF-Acadia Pharmaceuticals To Combine Clarity-2 And Clarity-3 Phase 3 Studies Evaluating Pimavanserin

* ACADIA PHARMACEUTICALS TO COMBINE CLARITY-2 AND CLARITY-3 PHASE 3 STUDIES EVALUATING PIMAVANSERIN FOR ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER

BRIEF-Acadia Pharmaceuticals Reports First Quarter 2020 Financial Results

* ACADIA PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Acadia Pharmaceuticals And Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation For Trofinetide

* ACADIA PHARMACEUTICALS AND NEUREN PHARMACEUTICALS ANNOUNCE RARE PEDIATRIC DISEASE DESIGNATION FOR TROFINETIDE FOR THE TREATMENT OF RETT SYNDROME

BRIEF-Acadia Pharmaceuticals Reports Q4 Loss Per Share $0.34

* ACADIA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

Acadia Pharma's psychosis drug proven better than placebo in dementia patients

Acadia Pharmaceuticals Inc said on Wednesday dementia patients taking its drug Nuplazid were nearly three times less prone to a psychotic relapse than those on placebo.

Acadia's schizophrenia treatment misses late-stage main goal; shares fall 16%

Acadia Pharmaceuticals Inc said on Monday its add-on treatment for schizophrenia failed to meet the main goal in a late-stage study.

Acadia's schizophrenia treatment fails to meet main goal of late-stage study

Acadia Pharmaceuticals Inc said on Monday its add-on treatment for schizophrenia failed to meet the main goal in a late-stage study.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up